Published in J Med Genet on February 01, 2004
Developing Family Healthware, a family history screening tool to prevent common chronic diseases. Prev Chronic Dis (2008) 2.20
Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet (2005) 2.13
Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin (2011) 1.90
Cancer family history characterization in an unselected cohort of 121 patients with uveal melanoma. Fam Cancer (2010) 1.68
Familial risk of early and late onset cancer: nationwide prospective cohort study. BMJ (2012) 1.56
"Monoallelic germline methylation and sequence variant in the promoter of the RB1 gene: a possible constitutive epimutation in hereditary retinoblastoma". Clin Epigenetics (2016) 1.47
Impact of the Cancer Risk Intake System on patient-clinician discussions of tamoxifen, genetic counseling, and colonoscopy. J Gen Intern Med (2005) 1.22
Colorectal cancer screening in 3 racial groups. Am J Health Behav (2007) 1.21
Awareness, perceptions, and provider recommendation related to genetic testing for hereditary breast cancer risk among at-risk Hispanic women: similarities and variations by sub-ethnicity. J Genet Couns (2010) 1.14
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol (2013) 1.13
Interviews with primary care physicians regarding taking and interpreting the cancer family history. Fam Pract (2008) 1.13
Development and validation of a primary care-based family health history and decision support program (MeTree). N C Med J (2013) 1.07
Primary care physicians' use of family history for cancer risk assessment. BMC Fam Pract (2010) 1.04
Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. J Med Genet (2004) 0.98
A pilot study of hereditary breast and ovarian knowledge among a multiethnic group of Hispanic women with a personal or family history of cancer. Genet Test Mol Biomarkers (2010) 0.96
The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence. Hered Cancer Clin Pract (2006) 0.95
Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control (2012) 0.93
"You don't have to keep everything on paper": African American women's use of family health history tools. J Community Genet (2013) 0.92
Patient and primary care provider experience using a family health history collection, risk stratification, and clinical decision support tool: a type 2 hybrid controlled implementation-effectiveness trial. BMC Fam Pract (2013) 0.91
Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol (2013) 0.91
The Swedish family-cancer database: update, application to colorectal cancer and clinical relevance. Hered Cancer Clin Pract (2005) 0.90
Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients. Ophthalmic Genet (2015) 0.90
Cancer genetic predisposition: information needs of patients irrespective of risk level. Fam Cancer (2009) 0.89
The evolution of colorectal cancer genetics-Part 1: from discovery to practice. J Gastrointest Oncol (2014) 0.88
Exploring hereditary cancer among dying cancer patients--a cross-sectional study of hereditary risk and perceived awareness of DNA testing and banking. J Genet Couns (2010) 0.88
Next-Generation Testing for Cancer Risk: Perceptions, Experiences, and Needs Among Early Adopters in Community Healthcare Settings. Genet Test Mol Biomarkers (2015) 0.88
Randomized Trial of Telegenetics vs. In-Person Cancer Genetic Counseling: Cost, Patient Satisfaction and Attendance. J Genet Couns (2015) 0.84
Cancer Visibility among Iranian Familial Networks: To What Extent Can We Rely on Family History Reports? PLoS One (2015) 0.83
Population screening for hereditary and familial cancer syndromes in Valka district of Latvia. Hered Cancer Clin Pract (2010) 0.82
Single nucleotide polymorphisms (SNPs) are inherited from parents and they measure heritable events. J Carcinog (2005) 0.81
Do people really know what makes a family history of cancer? Health Expect (2012) 0.80
Impact of familial risk factors on management and survival of early-onset breast cancer: a population-based study. Br J Cancer (2006) 0.80
Ingredients for success: a familial cancer clinic in an oncology practice setting. J Oncol Pract (2011) 0.79
Lack of GNAQ germline mutations in uveal melanoma patients with high risk for hereditary cancer predisposition. Fam Cancer (2011) 0.78
Hereditary cancer risk assessment: essential tools for a better approach. Hered Cancer Clin Pract (2013) 0.78
Clinically relevant lessons from Family HealthLink: a cancer and coronary heart disease familial risk assessment tool. Genet Med (2014) 0.76
BRCA Testing in Serbia and Montenegro. Hered Cancer Clin Pract (2006) 0.75
The recurrence risk of genetic complex diseases. J Res Med Sci (2017) 0.75
A model for patient-direct screening and referral for familial cancer risk. Fam Cancer (2016) 0.75
Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing. Cancer Biol Med (2016) 0.75
Clinical vignette: early-onset head and neck cancer: beware of fanconi anaemia! Hered Cancer Clin Pract (2004) 0.75
Clinical utility of a Web-enabled risk-assessment and clinical decision support program. Genet Med (2016) 0.75
Contribution of extended family history in assessment of risk for breast and colon cancer. BMC Fam Pract (2016) 0.75
Concerns about inherited risk of breast cancer prior to diagnosis in Japanese patients with breast complaints. Fam Cancer (2011) 0.75
Hereditary and non-hereditary branches of family eligible for BRCA test: cancers in other sites. Hered Cancer Clin Pract (2017) 0.75
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst (1989) 19.87
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med (1997) 13.96
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology (1999) 11.94
The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum (1991) 9.82
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med (1998) 8.47
Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology (2000) 8.41
Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med (2002) 6.94
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst (1999) 6.48
Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst (1994) 6.27
A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst (1997) 5.68
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06
Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer (1994) 4.37
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med (1997) 4.33
Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med (1995) 4.10
Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol (2000) 3.98
Assessing the risk of breast cancer. N Engl J Med (2000) 3.72
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet (2002) 3.67
CDKN2A mutations in multiple primary melanomas. N Engl J Med (1998) 3.52
Family history and the risk of prostate cancer. Prostate (1990) 3.27
Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res (1994) 3.20
Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet (2000) 3.12
Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet (1998) 2.90
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst (1997) 2.80
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA (1997) 2.78
Cancer risk in relatives of patients with common colorectal cancer. Ann Intern Med (1993) 2.61
Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet (1998) 2.59
Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res (1997) 2.27
Screening and genetic counselling for relatives of patients with colorectal cancer in a family cancer clinic. BMJ (1990) 2.17
Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet (1999) 2.12
Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet (2000) 2.05
A population-based case-control study of thyroid cancer. J Natl Cancer Inst (1987) 1.98
Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer (2000) 1.90
Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res (1991) 1.89
Identification and referral of families at high risk for cancer susceptibility. J Clin Oncol (2002) 1.80
Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer (2000) 1.75
An investigation of the familial aspects of carcinoma of the prostate. Cancer (1960) 1.75
Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet (2000) 1.65
Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol (1992) 1.63
Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet (1999) 1.57
The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat (1993) 1.50
Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol (1999) 1.47
Cancer in the families of children with soft tissue sarcoma. Cancer (1990) 1.47
Familial patterns of prostate cancer: a case-control analysis. J Urol (1991) 1.45
Prostate cancer risk in U.S. blacks and whites with a family history of cancer. Int J Cancer (1995) 1.43
Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int J Cancer (1995) 1.38
High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst (1994) 1.33
Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet (2001) 1.26
American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology (2001) 1.24
Genetic testing for cancer predisposition. Annu Rev Med (2001) 1.21
The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery (1998) 1.17
Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer (1995) 1.10
Proportion of heritable paraganglioma cases and associated clinical characteristics. Laryngoscope (2001) 1.02
Common hereditary cancers and implications for primary care. Lancet (2001) 0.92
Graphs to estimate an individualized risk of breast cancer. J Clin Oncol (1996) 0.92
Predictive testing for germline mutations in the p53 gene: are all the questions answered? Eur J Cancer (1993) 0.88
A computer program for estimating individualized probabilities of breast cancer. Comput Biomed Res (1993) 0.87
Agreement between breast cancer risk estimation methods. J Natl Cancer Inst (1996) 0.83
Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst (2000) 16.92
Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 10.71
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature (1995) 6.16
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (1993) 5.81
Is secondary haemorrhage after tonsillectomy in adults an infective condition? Objective measures of infection in a prospective cohort. Clin Otolaryngol (2007) 5.45
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A (1997) 5.32
Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet (1997) 4.86
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA (1997) 4.79
Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet (1998) 4.72
Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet (2001) 4.71
Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet (1997) 4.39
Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet (2005) 4.14
Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science (1993) 3.89
Complete transformation by adenovirus 2 requires both E1A proteins. Cell (1984) 3.80
Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet (2001) 3.58
Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53
PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet (1999) 3.22
BCL-6 protein is expressed in germinal-center B cells. Blood (1995) 3.18
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet (1996) 2.97
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet (1996) 2.93
The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev (2001) 2.87
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet (1996) 2.82
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol (1999) 2.79
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA (1997) 2.78
BRCA-associated breast cancer in young women. J Clin Oncol (1998) 2.78
Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet (2001) 2.77
Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell (1999) 2.71
Pneumococcal bacteraemia in two immunocompetent adults with otitis media and bronchitis. Lancet (1990) 2.59
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol (1998) 2.55
Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood (1994) 2.38
Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A (2001) 2.38
Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet (2004) 2.29
Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol (2000) 2.27
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol (2000) 2.23
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A (2000) 2.23
Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet (2000) 2.15
Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. JAMA (1999) 2.14
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet (1994) 2.14
Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci U S A (1995) 2.13
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet (1999) 2.08
Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res (1997) 2.06
Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet (2000) 2.05
Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol (2000) 2.05
Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene. J Lipid Res (2001) 2.02
Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome). Nat Genet (1996) 2.01
PTEN mutations in gliomas and glioneuronal tumors. Oncogene (1998) 2.01
TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res (1999) 1.99
Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene (1998) 1.97
22q13 deletion syndrome. Am J Med Genet (2001) 1.94
PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet (2001) 1.87
Molecular characterisation of a common SDHB deletion in paraganglioma patients. J Med Genet (2007) 1.86
PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res (1999) 1.85
Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet (2000) 1.84
Molecular identification of latent precancers in histologically normal endometrium. Cancer Res (2001) 1.84
Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA (1995) 1.83
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol (2001) 1.82
Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am J Hum Genet (2001) 1.81
Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res (2000) 1.78
The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet (2002) 1.77
Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nat Genet (1996) 1.74
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst (1999) 1.73
Targeted mutagenesis of Smad1 reveals an essential role in chorioallantoic fusion. Dev Biol (2001) 1.71
PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum Mol Genet (2001) 1.69
Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res (1998) 1.68
Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet (1995) 1.68
Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. Hum Mol Genet (2001) 1.66
Carney complex, Peutz-Jeghers syndrome, Cowden disease, and Bannayan-Zonana syndrome share cutaneous and endocrine manifestations, but not genetic loci. J Clin Endocrinol Metab (1998) 1.63
Germline SDHD mutation in familial phaeochromocytoma. Lancet (2001) 1.62
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61
Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer (2012) 1.61
Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood (1998) 1.60
Screening mammography for frail older women: what are the burdens? J Gen Intern Med (2001) 1.59
Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation (1999) 1.59
Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene (2000) 1.58
Integrating acute and long-term care for high-cost populations. Health Aff (Millwood) (2001) 1.57
PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet (2001) 1.56
Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer (1999) 1.54
A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2001) 1.51
Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet (1994) 1.51
Germline PTEN mutations in Cowden syndrome-like families. J Med Genet (1998) 1.51
Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood (1992) 1.51
Germline mutations of the RET ligand GDNF are not sufficient to cause Hirschsprung disease. Nat Genet (1996) 1.49
Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet (2002) 1.48
Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome. Cancer Res (1997) 1.47
Genetic prognostic markers for colorectal cancer. N Engl J Med (2000) 1.46
Myocardial micronecrosis produced by microsphere embolization. Role of an alpha-adrenergic tonic influence on the coronary microcirculation. Circ Res (1984) 1.43
Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation. Genes Chromosomes Cancer (1998) 1.43
Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol (2001) 1.42
Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene (2008) 1.41
p53 mutations are associated with histologic transformation of follicular lymphoma. Blood (1993) 1.40
A novel germline mutation of the PTEN gene in a patient with macrocephaly, ventricular dilatation, and features of VATER association. J Med Genet (2001) 1.40
Reduced employment in caregivers of frail elders: impact of ethnicity, patient clinical characteristics, and caregiver characteristics. J Gerontol A Biol Sci Med Sci (2001) 1.37
The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet (1997) 1.37
REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood (1996) 1.35
Analysis of genetic and phenotypic heterogeneity in juvenile polyposis. Gut (2000) 1.34
Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. Breast Cancer Res Treat (2011) 1.33
Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol (2010) 1.31